VNDA
NASDAQ · Biotechnology
Vanda Pharmaceuticals Inc
$5.04
-0.17 (-3.26%)
Open$5.32
Previous Close$5.21
Day High$5.33
Day Low$5.00
52W High$9.94
52W Low$4.27
Volume—
Avg Volume700.6K
Market Cap307.76M
P/E Ratio—
EPS$-4.05
SectorBiotechnology
Analyst Ratings
Strong Buy
10 analysts
Price Target
+206.5% upside
Current
$5.04
$5.04
Target
$15.45
$15.45
$11.33
$15.45 avg
$18.37
Key Financials
| FY 2026 | FY 2025 | FY 2024 | |
|---|---|---|---|
| Revenue | 221.72M | 234.11M | 122.09M |
| Net Income | -226,209,045 | -214,959,497 | 12.67M |
| Profit Margin | -102.0% | -96.9% | 10.4% |
| EBITDA | -147,909,867 | -148,362,763 | 21.61M |
| Free Cash Flow | — | — | 20.08M |
| Rev Growth | -5.3% | -5.3% | +22.8% |
| Debt/Equity | 0.02 | 0.02 | 0.48 |
Biotechnology Peers
| Symbol | Name | Price | Change | P/E | Mkt Cap |
|---|---|---|---|---|---|
| ABBV | Abbvie Inc | $265.08 | -0.05% | 74.0 | 466.74B |
| AMGN | Amgen Inc | $406.09 | -1.01% | 23.7 | 207.25B |
| GILD | Gilead Sciences Inc | $151.37 | -0.85% | — | 187.10B |
| VRTX | Vertex Pharmaceuticals Inc | $516.34 | +0.26% | 29.7 | 130.64B |
| REGN | Regeneron Pharmaceuticals | $801.82 | -0.26% | 18.6 | 80.58B |
| ALNY | Alnylam Pharmaceuticals Inc | $246.51 | -2.04% | 40.0 | 32.33B |